CD38 and Miyoshi myopathy: Daratumumab as a monoclonal antibody (mAb) targeting CD38, CD38-specific CAR-T cells and bispecific antibodies to stimulate T cells to eliminate CD38+ MM cells is a very effective therapeutic approach [48].